Primary endpoint of the study is OR, while among secondary endpoints are time to tumor response (TTR), DR, PFS, OS, time to prostate-specific antigen (PSA) progression for castration-resistant metastatic prostate cancer (mCRPC) patients, and pharmacokinetic parameters. Here, KLK3 is linked to metastatic prostate carcinoma.